EUVIMEDEUVIMED entdecken
Crossref

Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study

Guoyi Yang, C Mary Schooling iD

The Journal of Clinical Endocrinology & Metabolism · 17.01.2023 · 108 (2) · 385-396

DOI: 10.1210/clinem/dgac562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.10.2022. Verfasst von Guoyi Yang und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Statins and possibly other lipid modifiers increase type 2 diabetes risk and body mass index (BMI). However, to what extent BMI mediates the diabetogenic effects of lipid modifiers remains unclear.

Objective

We used Mendelian randomization (MR) to investigate the effects of commonly used lipid modifiers on type 2 diabetes risk and glycemic traits, and any mediation by BMI.

Methods

Using established genetic variants to mimic commonly used lipid modifiers (ie, statins, PCSK9 inhibitors, and ezetimibe), we assessed their associations with type 2 diabetes risk, glycated hemoglobin (HbA1c), fasting insulin, fasting glucose, and BMI in the largest relevant genome-wide association studies (GWAS) in people of European ancestry, and where possible, in East Asians. We used multivariable MR to examine the role of lipid modifiers independent of BMI.

Results

Genetically mimicked effects of statins and ezetimibe, but not PCSK9 inhibitors were associated with higher risk of type 2 diabetes (odds ratio [OR] 1.74 [95% CI, 1.49 to 2.03]; 1.92 [1.22 to 3.02]; 1.06 [0.87 to 1.29] per SD reduction in low-density lipoprotein (LDL)-cholesterol). Of these lipid modifiers, only genetic mimics of statins were associated with higher BMI (0.33 SD [0.29 to 0.38] per SD reduction in LDL-cholesterol), which explained 54% of the total effect of statins on type 2 diabetes risk.

Conclusion

Higher BMI mediated more than half of the diabetogenic effects of statins, which did not extend to other commonly used lipid modifiers. Further investigations are needed to clarify drug-specific mechanisms underlying the effects of lipid modifiers on type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsHumansBody Mass IndexGenome-Wide Association StudyMendelian Randomization AnalysisBlood GlucosePolymorphism, Single NucleotideLipidsEzetimibeRisk FactorsProprotein Convertase 9

Stichwörter der Autor:innen

Mendelian randomizationbody mass indexglycemic traitsstatinstype 2 diabetes

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsBlood GlucoseLipidsEzetimibePCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China.
  • Graduate School of Public Health and Health Policy, City University of New York, New York 10027, USA.

ORCID-Profile: C Mary Schooling

Zitieren

APA

Yang, G., & Schooling, C. M. (2023). Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study. The Journal of Clinical Endocrinology & Metabolism, 108(2), 385-396. https://doi.org/10.1210/clinem/dgac562

Vancouver

Yang G, Schooling CM. Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study. The Journal of Clinical Endocrinology & Metabolism. 2023;108(2):385-396. doi:10.1210/clinem/dgac562

BibTeX
@article{Yang2023,
  author = {Yang, Guoyi and Schooling, C Mary},
  title = {Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {2},
  pages = {385--396},
  doi = {10.1210/clinem/dgac562}
}
Kostenlos starten →